financetom
Business
financetom
/
Business
/
Market Chatter: Apple, Alibaba AI Rollout in China Delayed by Regulators Amid Rising US-China Tensions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Apple, Alibaba AI Rollout in China Delayed by Regulators Amid Rising US-China Tensions
Jun 4, 2025 9:57 AM

12:44 PM EDT, 06/04/2025 (MT Newswires) -- Apple's ( AAPL ) rollout of its artificial intelligence services in China, developed with Alibaba Group ( BABA ) , is being held up by Chinese regulators, as US-China trade tensions intensify, the Financial Times reported Wednesday, citing people familiar with the situation.

The AI suite, called "Apple Intelligence," relies on Alibaba's ( BABA ) latest models and is part of Apple's ( AAPL ) strategy to expand its presence in China's competitive smartphone market, the report said.

The companies have submitted multiple AI products to the Cyberspace Administration of China for approval this year, but the process has stalled, two sources told the FT.

President Donald Trump has threatened steep tariffs unless Apple ( AAPL ) shifts manufacturing back to the US, as the company faces AI rollout delays and growing competition from Chinese brands like Huawei, the FT said.

Final clearance for Apple Intelligence in China must come from China's State Council, which is also involved in ongoing trade negotiations with the US. However, decisions could accelerate if broader diplomatic conditions improve, the report said.

Apple ( AAPL ) declined to comment to the FT, while Alibaba ( BABA ), the Cyberspace Administration of China and the Chinese State Council did not respond.

Apple ( AAPL ), Alibaba ( BABA ), and the Chinese State Council didn't immediately respond to a request for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 202.73, Change: -0.54, Percent Change: -0.27

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ITT's Q4 Adjusted Earnings, Revenue Increase; 2025 Guidance Initiated; Quarterly Dividend Raised
ITT's Q4 Adjusted Earnings, Revenue Increase; 2025 Guidance Initiated; Quarterly Dividend Raised
Feb 6, 2025
06:45 AM EST, 02/06/2025 (MT Newswires) -- ITT (ITT) reported Q4 adjusted earnings Thursday of $1.50 per diluted share, up from $1.34 a year earlier. Analysts polled by FactSet expected $1.47. Revenue for the quarter ended Dec. 31 was $929 million, up from $829.1 million a year earlier. Analysts surveyed by FactSet expected $927 million. The company initiated 2025 adjusted...
AllianceBernstein Q4 Adjusted Net Income, Total Revenue Increase; Quarterly Distribution Declared
AllianceBernstein Q4 Adjusted Net Income, Total Revenue Increase; Quarterly Distribution Declared
Feb 6, 2025
06:45 AM EST, 02/06/2025 (MT Newswires) -- AllianceBernstein Holding ( AB ) reported Q4 adjusted net income Thursday of $1.05 per diluted unit, up from $0.77 a year earlier. Analysts polled by FactSet expected $0.86. Total revenue for the quarter ended Dec. 31 was $1.28 billion, up from $1.12 billion a year earlier. Analyst estimates were not readily available for...
Kenvue sees 2025 profit below estimates as strong dollar, weak cough product sales hit
Kenvue sees 2025 profit below estimates as strong dollar, weak cough product sales hit
Feb 6, 2025
Feb 6 (Reuters) - Consumer health company Kenvue ( KVUE ) forecast 2025 adjusted profit below Wall Street estimates on Thursday, hit by a stronger dollar and weak demand for its cough and cold products that include Tylenol and Benadryl. The company, which was spun off from Johnson & Johnson ( JNJ ) in 2023, has been under pressure from...
Lear's Q4 Adjusted Earnings, Sales Fall; Provides Full-Year Sales Outlook
Lear's Q4 Adjusted Earnings, Sales Fall; Provides Full-Year Sales Outlook
Feb 6, 2025
06:44 AM EST, 02/06/2025 (MT Newswires) -- Lear (LEA) reported Q4 adjusted earnings Thursday of $2.94 per share, down from $3.03 a year earlier. Analysts polled by FactSet expected $2.58. Sales for the quarter ended Dec. 31 were $5.72 billion, down from $5.84 billion a year earlier. Analysts surveyed by FactSet expected $5.53 billion. For full-year 2025, the company said...
Copyright 2023-2026 - www.financetom.com All Rights Reserved